|
業務類別
|
Biotechnology |
|
業務概覽
|
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02. |
| 公司地址
| 2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103 |
| 電話號碼
| +1 267 866-0311 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.passagebio.com |
| 員工數量
| 24 |
| Ms. Kathleen Borthwick |
Chief Financial Officer and Principal Accounting Officer |
美元 450.63K |
07/04/2026 |
| Dr. William Chou, M.D. |
Director, President and Chief Executive Officer |
美元 660.99K |
07/04/2026 |
|
|
| Dr. William Chou, M.D. |
Director, President and Chief Executive Officer |
07/04/2026 |
| Dr. Dolan Sondhi, PhD |
Independent Director |
07/04/2026 |
| Dr. Maxine Gowen,PhD |
Chairwoman of the Board |
07/04/2026 |
| Dr. Derrell D. Porter, M.D. |
Independent Director |
07/04/2026 |
| Mr. Sandip S. Kapadia, C.P.A.,M.B.A. |
Independent Director |
07/04/2026 |
| Dr. Athena Countouriotis, M.D. |
Independent Director |
07/04/2026 |
| Mr. Thomas R. Kassberg |
Independent Director |
07/04/2026 |
|
|
|
|
